• 1
    Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 2003; 196: 85108.
  • 2
    Gudmundsdottir H, Turka LA. T cell costimulatory blockade: New therapies for transplant rejection. J Am Soc Nephrol 1999; 10: 13561365.
  • 3
    Aoyagi T, Yamashita K, Suzuki T, et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: Induction and maintenance therapy. Am J Transplant 2009; 9: 17321741.
  • 4
    Miura T, Okimura K, Takahash iN, Kataoka S. Pharmacological and toxicological studies of a fully human antibody (4D11) against human CD40 in human samples in vitro and nonhuman primates in vivo. Am J Transplant 2005; 5(11 Suppl): 420.
  • 5
    Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007; 84: 10201028.
  • 6
    Kernstock R. Bioanalytical Validation Report IC-2009–001. Validation of an Analytical Method for the Determination of ASKP1240 in Human Serum using Electrochemiluminescence. February 26, 2010. Skokie, IL, USA: Astellas Pharma Global Development, Inc.; 2010.
  • 7
    Kernstock R. Bioanalytical Validation Report IC-2009–002. Validation of an analytical method for the screening, confirmation, and titer for the presence of anti-ASKP1240 antibodies in human serum using electrochemiluminescence detection. February 26, 2010. Skokie, IL, USA: Astellas Pharma Global Development, Inc.; 2010.
  • 8
    Kirk AD, Knechtle SJ, Vincenti FG, Nadeau KC. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation [abstract] Am J Transplant 2001; 1(Suppl 1): 191.
  • 9
    Boumpas DT, Furie R, Manzi S, Illei GG, et al. A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheumatism 2003; 48: 719727.
  • 10
    Pree I, Wekerle T. New approaches to prevent transplant rejection: Co-stimulation blockers anti-CD40L and CTLA41g. Drug Discov Today 2006; 3: 4147.
  • 11
    Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13: 391397.
  • 12
    Tabrizi MA, Tseng CL, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discoveries Therapeutics 2006; 11: 8188.
  • 13
    Bensinger W, Maziarz RT, Jagannath S, et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology 2012; 159: 5866.
  • 14
    Advani R, Forero-Torres A, Furman RR, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 43714377.
  • 15
    Hussein M, Berenson JR, Niesvizky R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010; 95: 845848.
  • 16
    Kasran A, Boon L, Wortel CH, et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005; 22: 111122.
  • 17
    Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25: 876883.